| Project/Area Number |
63044077
|
|---|
| Research Category |
Grant-in-Aid for international Scientific Research
|
| Allocation Type | Single-year Grants |
|---|
| Section | Joint Research |
|---|
| Research Institution | Kyoto University Faculty of Medicine |
|---|
Principal Investigator |
UEDA Kunihiro (1990) Kyoto University Faculty of Medicine, 医学部, 助教授 (00027070)
上田 国寛 (1990) 京都大学, 医学部, 助教授
村地 孝 (1988-1989) 京都大, 医, 教授
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KANNAGI Reiji Kyoto University Faculty of Medicine, 医学部, 講師 (80161389)
山肩 葉子 京都大学, 医学部, 助手 (20210338)
HAMAKUBO Takao Kyoto University Faculty of Medicine, 医学部, 助手 (90198797)
RUCHANEELKOR カルプラヴイド マヒドール大学, 医学部タイ国, 助教授
PRAPON Wilairat Mahidol University, School of Science, 理学部タイ国, 教授
FUCHAROEN Suthat Mahidol University, Faculty of Graduate Studies, 大学院タイ国, 教授
ADACHI Yoshifumi Kyoto University Faculty of Medicine, 医学部, 助手 (50201893)
TOTANI Masayuki National Institute of Health and Nutrition, 母子健康栄養部, 部長 (70163988)
RUCHANEELKORN Kalparavid Mahidol University, School of Medicine
YMAMGATA Yoko Kyoto University Faculty of Medicine
MURACHI Takashi Kyoto University Faculty of Medicine
|
|---|
| Project Period (FY) |
1988 – 1990
|
| Project Status |
Completed (Fiscal Year 1990)
|
| Budget Amount *help |
¥5,100,000 (Direct Cost: ¥5,100,000)
Fiscal Year 1990: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 1989: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 1988: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | Thalassemia / Globin Genes / Hemoglobinopathy / Proteolysis / Calpain / Calpastatin / Ca^<2+> / Membrane Proteins |
|---|
| Research Abstract |
According to our original plan, we, Japanese and Thai, studies the mechanisms of abnormal proteolysis in the red blood cell of thalassemic patients, by exchanging material and information. Our analysis at clinical and molecular levels indicated that phenotypic manifestation of the disease is influenced not only by mutated genotypes but also by other factors ; the red cells of beta-thallasemia/Hb E patients with similar genetic defects were not always similar but variable in the hemoglobin content. We tentatively identified the following three factors that may modify clinical manifestation of thalassemia ; an interaction between alpha- and beta-thalassemia genes or their products, a structure or function of HbF gene, and Hb F gene, and protease activities. The first factor was suggested by the finding of amiliolated severity of beta-thalassemic patients with alpha-thalassemia gene. The second factor was indicated by the finding that homozygotes (+/+) with regard to XmuI restriction site (158 mucleotides upstream from the ^Ggamma gene) in the beta-globin gene cluster had significantly higher levels of hemoglobin than heterozygoted (+/-) of homozygotes (-/-). The last factor was suggested by a higher activity of calpain (Ca^<2+>-dependent cysteine protease), though accompanied by a higher activity of calpastatin (an endogenous inhibitor of calpain), in thalassemic red cells than in normal cells. Partial degradation of membrane proteins was also detected in thalassemic red cells. These results indicate the importance of the ratio of alpha- and beta-type globins as well as the activity of proteases in clinical investigation of thalassemia.
|
